Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Interest Coverage Ratio (2020 - 2022)

Inhibikase Therapeutics (IKT) has disclosed Interest Coverage Ratio for 3 consecutive years, with 928119.2 as the latest value for Q1 2022.

  • Quarterly Interest Coverage Ratio fell 416962.55% to 928119.2 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was 3625721.6 through Dec 2022, down 489095.22% year-over-year, with the annual reading at 741.16 for FY2021, 673.17% down from the prior year.
  • Interest Coverage Ratio for Q1 2022 was 928119.2 at Inhibikase Therapeutics, down from 31907.98 in the prior quarter.
  • The five-year high for Interest Coverage Ratio was 52.08 in Q2 2020, with the low at 928119.2 in Q1 2022.
  • Average Interest Coverage Ratio over 3 years is 109939.28, with a median of 222.54 recorded in 2021.
  • The sharpest move saw Interest Coverage Ratio crashed 205.98% in 2021, then tumbled 416962.55% in 2022.
  • Over 3 years, Interest Coverage Ratio stood at 168.21 in 2020, then plummeted by 18869.2% to 31907.98 in 2021, then tumbled by 2808.74% to 928119.2 in 2022.
  • According to Business Quant data, Interest Coverage Ratio over the past three periods came in at 928119.2, 31907.98, and 28477.96 for Q1 2022, Q4 2021, and Q3 2021 respectively.